Interest of Measuring Lung Elasticity ELASTOgraphy in the Fetus in the Case of PreMAture Childbirth Threat
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 103
- Locations
- 1
- Primary Endpoint
- Evolution over 48 hours of the fetal lung elasticity coefficient measure in kilopascals (kPa) (compared to the fetal liver)
Study Overview
Brief Summary
The objective of the study was to evaluated the feasibility and reproducibility of the measurement of lung elasticity report / fetal liver according to gestational age in a group of patients with a normal course of pregnancy and in a group of Patients at risk of preterm delivery.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •for control group :
- •major pregnant women
- •singleton pregnancy
- •Inclusion Criteria for control group :
- •major pregnant women
- •singleton pregnancy
- •hospitalized for threatened premature birth between 24 and 34 WA
- •Indication of a cure corticosteroid betamethasone
Exclusion Criteria
- •maternal conditions of pregnancy: diabetes gestational, pregnancy-induced hypertension, preeclampsia
- •fetal lung diseases
Arms & Interventions
preterm labor group
Pregnant women hospitalized for preterm labor
Intervention: lung and liver elastography measurement of fetus (Other)
control group
Pregnant women with a normal pregnancy
Intervention: lung and liver elastography measurement of fetus (Other)
Outcomes
Primary Outcomes
Evolution over 48 hours of the fetal lung elasticity coefficient measure in kilopascals (kPa) (compared to the fetal liver)
Time Frame: For pretern larbor group: day of hospitalization for preterm labor, then 2 days later. For control group, both measurements at 2-day intervals
The dates of elastography exams controls patients will be distributed a week of amenorrhea (WA) between 24 and 34 WA.
Secondary Outcomes
No secondary outcomes reported